Pitches from Emerging Startups

Modera: Liz Fleming

Alejandro Alonso PuigQUARK ROBOTICS

CruiserBot Project

Alejandro Alonso

aalonso@quarkrobotics.com

The Problem

Biological poluting agents

Respiratory problems

Air ducts

The Competitors

Sell Big and Heavy solutions, or Low quality solutions, or Good quality, but complex and

expensive

• Portable• Modular• Easy to use• International

Our Solution

Ozone

disinfection

Cleaning

+ MODULES

INSPECTION

• Cleaning companies• Construction companies• Duct installation companies• Certification & Technical consultancy• Pest control companies• Civil Security

• …and more as soon as we create additional modules

The Market

• 8 shareholders (6 family + 2 friends)

• 180K€ funding for R&D and production of the 10 first saleable units

The Team

CEO: More than 15 years in management possitions in 4 companies

R&D people: more than 10 years developing robotic solutions

Sales people: More than 20 years selling technical products

• Extend business to the rest of the country• Establish active business agreements in 4 more countries• 900.000€ revenue / 150 customers• 23% accumulated gross profit (36% in 2nd year)• Improve product, reduce manufacturing costs and produce additional

modules• 200.000€ round of funding

Next Steps (2 years plan)

Alejandro AlonsoFounder & CEOQuark Robotics

aalonso@quarkrobotics.comCell: +34-600912305

More information and videos about the product:

www.cruiserbot.com

Sindhu JosephCOGNICOR

Business Need

Business Need

Business Need

100 000+ complaint

s

100 000+ complaint

s

€3billion

Our Solution

Competition

cost/time per complaints

Com

plex

ity o

f Com

plai

nts

Business Model

Complaints/Year

<50 000 <200 000 200 000+

Cost €170,000 €680,000 €1,700,000

“Resolution as a Service”

Projection

Year 2012 2013 2014

Clients 3 8 16

Net Revenue

€250,000 €890,000 €2.6M

Ground Covered

Expr

esse

d in

tere

st

Beta

Clie

nts

Prod

uct D

evel

opm

ent

Busi

ness

Pla

n

2011 2012

Cogn

icor

Inco

rpor

ated

Payi

ng C

lient

s

Acce

lera

tion

by W

ayra

Team

CEODirectorBusiness

Development

DirectorProduct Development

PhD in Artificial IntelligenceResearch EngineerInventor of 6 US technology patents

MBA, ESADE Business SchoolEntrepreneurSeasoned IT ConsultantInsurance Industry Expertise7 years of USA work experience

Master of Computer EngineeringCommercial Product design & developmentTelecom Industry Expertise

WinnerSpinoff

Finalist

In the Media

BDigital Innovation Award, 2012

Iñigo SerranoEMTRICS

Iñigo SerranoCEO

Eduard GiménezCTO

Mobility

Telecom

M&A

Tech

Systems Engineering

Scalability

Backend Engineering

Software Engineerig

The founding team

50 merchants with more than150 pilots

• +33% Pilot Customers want it

• 17k€ sold in 1 month and a half.

France United Kingdom Italy Argentina

Portugal Belgium Netherlands Chile

EU market over 1Bn €

• Seed 1 (12/11): 120k€ raised• Seed 2 (06/12): 100k€ secured• Series A (exp. 12/12): 800k€

@emtricshttp://emtrics.com

Matthieu HeuschDOCTOR DOCTOR

doctordoctor

“Health made easy”

Matthieu HeuschCEO & Co-Founder

actual status

Private healthcare: 2,5% GDP+200.000 professionals+10.000.000 patients

Andalucia saves €12M / year

US: e-health = 0,5% GDP ($78B)

+ attractive industry for VCs

e-health market

Online Booking

Management App & CRM

Online Booking

Health Alerts & Reminders

Doctor DoctorCommunication& Relationship

Patients & Doctors

B2C B2B

1

ONLINE PRESENCE

SOFTWARE

+ ONLINE BOOKING

+

2

3

INTEGRATION PROJECTS

how do we add value now?

CRM+ 4

1

+

+

how do we do it?

B2CB2B

1

2

1

2

3 (white label)(white

label)

+700

+100.000

reach : +15.000

RFP: white label worldwide

achievements so far

nominated for best european app

MattCEO

Business & Partners

ChiscoCOO

Marketing& Product

DanielCTO

Technology& R&D

our team

Juan José Güemes

Healthcare

Enrique Dans

Technology

Emilio MoraledaPharma

Alfredo Biel

Health Tech

what are our next steps?

1

2

doctordoctor

“Health made easy”

@doctordoctores@matthieuheusch+34.665.93.17.64

Jonathan LevyTyler MaglioneINVOOST

• video

boring

COMPETITIVE

ENGAGING

EDUCATIONAL

MORE

• VIDEO

Market

Social Gamers

Fantasy SportsPlayers

Online Gamers

Market Traders

9,000,0001,000,000

100,000

Swedes

readers

Joinedreal money

stock tournament

€ 5PAID entry fee

10 € 5

players

entry fee

total

€ 5invoost

€ 50

€ 45winners

10% 90%

Virtual Money Real Trading

Competition

Users?

Affiliate Partner site with invoost

invoost.com

invoost.com

invoost.cominvoost.com

Stock

Championship

3.2 Millionunique visits!

3.8 Millionunique visits!

JohanWilsson

Tyler Maglione

JonathanLevy

AbelMuiño

Germandel Zotto

(marketing)

(operations)

(product)

(developer) (developer)

What are we looking for?

Investors Connectors Everyone

300k Partners Sign up!

Go Live UKMarketing

Product development

UKGermany

.com

• video

@invoostwww.invoost.com

hello@invoost.com

Winners of:

EmprendeGoIE Venture Days

Enrique Samper PhDNIMGENETICS

Enrique Samper Ph.D.President

esamper@nimgenetics.com

Leading Genetic Diagnostics

83

12 employees, 7 Ph.D

Sara Alvarez , MD, Ph.D, CMOChief Medical Geneticist

Enrique Samper, Ph.D, CEOMolecular Biologist

Juan Cruz Cigudosa, Ph.D, CSODirector Cytogenetics Lab

mental retardation convulsions

cardiac problems

10 yrs of medical tests

unknown diagnostic

Kleefstra syndrome

3 days, analyze the DNA

85

DNA arrays

100x more resolution fast (3d)

86

Specific arrays for early diagnostics

innovative test designs definitive diagnostics

early treatment

Malformations/ Retardation/ Autism

Familial cancer breast, colon and endocrine

2% world population 10% cancer patients

50 Hospitals and Biotechs Cash flow +

90% AGR in sales

• 0,2M€2009

• 0,4M€2010

• 0,7M€2011

• 1.3M€2012e

National Market

innovation in designsclinical experienceexcellent teaminternational markets

competitors

89

• 3M€2013 • 6M€2014

international potential

internationalization new technology

increase sales force

we need your help

2M€ equity (Series A)

leveraged 2M€ (Participative loans)

Parque Científico de MadridC/ Faraday, 7Campus de Cantoblanco28049 Madrid

Tel: +34 91 804 7760Cell      +34 647 426 518

esamper@nimgenetics.com

Thank you

María Gómez del PozueloWOMENALIA

Miguel RoncalesALPHASIP

NanoChips for Medical diagnostics

Bill Gates Foundation 700 million vaccines donation: Had saved at least 6,4 million lives bringing unexpensive care

UNEXPENSIVE CHIPS

Help Children to reach a better life & reforest the planet & Smart Energy EcoDesign

ACTUAL lifestyle OLD devices EXPENSIVE SLOW RESULTS

PREVENTION

SERENDIPITY

CARE

Fast reliable infarction fingertip Ipad Compatible

DETECTS 6 DRUGS ON A SALIVA SIP INSTANT DETECTION

Digital Signal Read out resultsThe ASI nanoprocessor, processes the digital signal inside the chip

PhD Brent M. Segal, PhD Miguel Roncalés MD Javier Roncalés, PhD Xavi Muñoz

Spin off HarvardBrent Segal wrotes 122 Patents

Nantero (2001) - aszenszor (2006)400 Patents

on Nanotubes Memories

AlphaSIP (2008) is created for Blood Uses LM adquires Space, Defense & Energy

AlphaSIP CAJAL4EU24 Mill EUR ENIAC

LM Send Nantero Memory to Space

We target the most expensive assays Cardio, Lethal Infectious Diseases & CTCs…

… Saving costs Moore´s law

(Flat TV Paradigm)

NANOTECH saves lives

• Nanotechnology is an applied science field dedicated to the control and manipulation of the matter in a scale smaller than a micrometer

(atomic and molecular scale)

• A nanometer is the thousand millionth part of a meter (10-9 meters)

Robust Proof of Concept

MOLAR CONCENTRATION

Septic

emia

TSH

Para

tohor

mon

a

FT4

Estra

diol, T

4, PSA T3

Neopte

vina

Cortis

ol

Fe

Fruct

osam

ina

Gluco

sa

N3

Zepto10-21

Atto10-18

Femto10-15

Pico10-12

Nano10-9

Micro10-6

Milli10-3M (mol/L)

Nat, PCR, Enzymatic Immunoassays Direct & enzymatic

1 10 100 1 10 100 1 10 100 1 10 100 1 10 100 1 10 100 1 10 100 1

Examples:

Preclinical & Clinical Essays

Basic R&Dlimited

few cases“Atto”

Femtomolar Sensitivity 2016 with adequate funding

EVOLUTION

MARKET OVER - 1,8 BILLION EURMain Figures• In Vitro Diagnostics market world-wide: 48.000 Mill EUR (2010)• European Coagulation market: 600 Mill EUR (2010)• 85.000 yearly infarctions in Spain, 28.000 deaths/year

DUAL BUSINESS MODEL

OEM 80%

“Alphasip Inside” 20%

• Business model maybe similar to other semicon providers like Intel strategy of convey “Intel Inside” on larger products defined by Global Leading IVD Suppliers to take advantage of the depth of their distribution capabilities

STRONG IP POSITION CARDIOSIP• 8 own Patents +400 Patents licensed CVD

400 PATENTS NANTERO CNTS FIELD EFFECT TRANSISTOR

The IEEE (Institute of Electric Engineers, 375.000 patrons in 160 countries) ranked in its January 2010 report the Nantero IP in 2nd place worldwide in the semicon industry and top 10 in overall industries

OUR INDUSTRIAL PARTNERS & CAJAL4EU

Multiply by 10x the investment in 4 years 78% IRR

Chip process facilitate mass production & significant growth

ALPHASIP ADVANTAGE

RESULTS ON IPAD & ANDROID BRIDGING POC & CENTRAL LABS

ALPHASIP’s alternative to ELISA method

- Fast diagnostic (1 to 3 min)

- Low unit cost

-“Nano”. Need less antibodies

- Portable device

- High sensitivity & specificity

- Ease of use

- Simple integration with

communication systems

(tablets, cell phones)

DIGITAL SIGNAL

CURRENT METHODS

- From 1 hour to 2 weeks- Requires expert personnel

- High unit cost- Device size

- Intrusive methods- Low sensitivity

Revolution

Contact Information:Miguel Roncalés (PhD)+34626004107+34976512887mroncales@alphasip.es